<div class=TRS_Editor><div class="TRS_PreAppend" style="overflow-x: hidden; word-break: break-all">
<p class="MsoNormal" style="layout-grid-mode: char; line-height: 150%; text-autospace: ; text-indent: 28pt"><span lang="EN-US" style="font-size: 14pt; layout-grid-mode: line; line-height: 150%">11</span><span style="font-size: 14pt; font-family: 宋体; layout-grid-mode: line; line-height: 150%">月</span><span lang="EN-US" style="font-size: 14pt; layout-grid-mode: line; line-height: 150%">11</span><span style="font-size: 14pt; font-family: 宋体; layout-grid-mode: line; line-height: 150%">日，</span><span style="font-size: 14pt; font-family: 宋体; line-height: 150%">华润双鹤发布公告，公司收到了国家药品监督管理局于</span><span lang="EN-US" style="font-size: 14pt; line-height: 150%">11</span><span style="font-size: 14pt; font-family: 宋体; line-height: 150%">月</span><span lang="EN-US" style="font-size: 14pt; line-height: 150%">4</span><span style="font-size: 14pt; font-family: 宋体; line-height: 150%">日颁发的普瑞巴林胶囊《药品注册证书》，批准该药生产。</span><span style="font-size: 14pt; font-family: 宋体; line-height: 150%">根据国家相关政策规定，本次获得视同通过一致性评价，由此</span><span style="font-size: 14pt; font-family: 宋体; line-height: 150%">华润双鹤成为第</span><span lang="EN-US" style="font-size: 14pt; line-height: 150%">2</span><span style="font-size: 14pt; font-family: 宋体; line-height: 150%">家视同通过该药品一致性评价的公司。普瑞巴林胶囊获批产将进一步丰富公司</span><span style="font-size: 14pt; font-family: 宋体; line-height: 150%">产品线，</span><span style="font-size: 14pt; font-family: 宋体; color: black; line-height: 150%">有利于该药品未来的市场销售和市场竞争，对公司经营业绩产生积极影响。</span></p>
<p class="Default" style="layout-grid-mode: char; text-align: justify; text-justify: inter-ideograph; line-height: 150%; text-indent: 28pt"><span style="font-size: 14pt; font-family: 宋体; line-height: 150%">普瑞巴林胶囊用于治疗带状疱疹后神经痛。其原研生产厂家为美国辉瑞制药公司，商品名为“</span><span lang="EN-US" style="font-size: 14pt; line-height: 150%">LYRICA<sup>？</sup></span><span style="font-size: 14pt; font-family: 宋体; line-height: 150%">”，</span><span lang="EN-US" style="font-size: 14pt; line-height: 150%">2004</span><span style="font-size: 14pt; font-family: 宋体; line-height: 150%">年</span><span lang="EN-US" style="font-size: 14pt; line-height: 150%">7</span><span style="font-size: 14pt; font-family: 宋体; line-height: 150%">月在欧盟获得批准上市，</span><span lang="EN-US" style="font-size: 14pt; line-height: 150%">2004</span><span style="font-size: 14pt; font-family: 宋体; line-height: 150%">年</span><span lang="EN-US" style="font-size: 14pt; line-height: 150%">10</span><span style="font-size: 14pt; font-family: 宋体; line-height: 150%">月在美国获得</span><span lang="EN-US" style="font-size: 14pt; line-height: 150%">FDA</span><span style="font-size: 14pt; font-family: 宋体; line-height: 150%">批准，</span><span lang="EN-US" style="font-size: 14pt; line-height: 150%">2010</span><span style="font-size: 14pt; font-family: 宋体; line-height: 150%">年在国内批准上市。中国境内已批准上市的该药品生产企业有</span><span lang="EN-US" style="font-size: 14pt; line-height: 150%">3</span><span style="font-size: 14pt; font-family: 宋体; line-height: 150%">家，其中</span><span lang="EN-US" style="font-size: 14pt; line-height: 150%">1</span><span style="font-size: 14pt; font-family: 宋体; line-height: 150%">家未形成销售。根据米内网数据显示，国内市场</span><span lang="EN-US" style="font-size: 14pt; line-height: 150%">2019</span><span style="font-size: 14pt; font-family: 宋体; line-height: 150%">年该药品销售总额（终端价）为</span><span lang="EN-US" style="font-size: 14pt; line-height: 150%">3.37</span><span style="font-size: 14pt; font-family: 宋体; line-height: 150%">亿元人民币。</span></p>
</div></div>
